Tsev Kawm Ntawv Qib Siab College London Tsev Kho Mob (UCLH) tau tshaj tawm kev tsis sib haum xeeb tshuaj tiv thaiv sim tawm tsam Covid-19. Daim ntawv tshaj tawm rau 25 Lub Kaum Ob Hlis 2020 hais tias ''UCLH koob tshuaj thawj zaug tus neeg mob hauv ntiaj teb hauv Covid-19 kev sim tshuaj tiv thaiv kab mob'' thiab '' Cov kws tshawb fawb hauv STORM CHASER txoj kev tshawb fawb coj los ntawm UCLH virologist Dr Catherine Houlihan tau nrhiav thawj tus neeg koom nrog hauv ntiaj teb rau txoj kev tshawb no'' (1).
Cov tshuaj tiv thaiv nyob rau hauv kev sim tshuaj hauv UCLH yog AZD7442 uas yog kev sib xyaw ntawm monoclonal tshuaj tiv thaiv (mAbs) tsim los ntawm AstraZeneca. Qhov kev sib xyaw ua ke no twb tau mus soj ntsuam kev sim hauv lub TEB CHAWS USA txij lub Kaum Ob Hlis 2, 2020 (2) . Ob peb lwm 'antibodies' thiab 'antibody Cocktails' tab tom raug kev sim tshuaj rau lwm qhov (3). Kev sib xyaw ua ke ntawm cov tshuaj tiv thaiv kab mob hauv AZD7442 tau hloov kho kom ncua lawv ib nrab-lub neej kom them taus kev tiv thaiv rau 12 txog XNUMX lub hlis. Qhov tseem ceeb tshaj plaws, lawv tau raug tsim kho kom txo qis Fc receptor binding uas lub hom phiaj txo qis qhov kev pheej hmoo ntawm cov tshuaj tiv thaiv kab mob los ntawm kev txhim kho cov kab mob - qhov tshwm sim uas cov tshuaj tiv thaiv kab mob rau tus kab mob txhawb nqa, es tsis txhob cuam tshuam kev kis kab mob. (4).
Cov tshuaj tiv thaiv neutralizing no yog cov cuab yeej tseem ceeb rau kev muab kev tiv thaiv rau cov neeg mob uas tsis muaj zog tiv thaiv kab mob thiab qhov chaw uas tus kab mob twb tau mus deb (3). Cov tshuaj tiv thaiv muab kev tiv thaiv kab mob, txawm li cas los xij kev tiv thaiv kev tiv thaiv los ntawm cov tshuaj tiv thaiv yuav siv sij hawm qee lub sij hawm thiab tej zaum yuav ua tsis tau zoo tom qab kis tau tus kab mob. Muab kev tiv thaiv kab mob los ntawm kev npaj ua, exogenous antibody yog txoj hauv kev los muab kev tiv thaiv sai rau cov neeg mob tiv thaiv kab mob thiab cov neeg mob uas muaj kab mob tag nrho.
Ob txoj kev tshawb fawb tau npaj. Txoj kev kawm STORM CHASER lub hom phiaj los ntsuas kev ua tau zoo ntawm monoclonal antibody AZD7442 rau kev tiv thaiv tam sim rau cov neeg uas nyuam qhuav kis tus kab mob SARS-CoV-2, tiv thaiv lawv tsim Covid-19; thaum lwm qhov kev tshawb fawb xws li PROVENT lub hom phiaj los ntsuas cov tshuaj tiv thaiv kab mob AZD7442 hauv cov neeg uas muaj kev cuam tshuam. tiv thaiv kab mob lub kaw lus uas yuav tsis teb rau cov tshuaj tiv thaiv lossis muaj kev pheej hmoo siab dua vim muaj yam xws li hnub nyoog thiab cov xwm txheej uas twb muaj lawm.
Kev tshawb fawb ntxiv thiab kev soj ntsuam soj ntsuam siv sib txawv ntawm kev sib txuas ntawm cov tshuaj tiv thaiv kab mob rau tus kab mob SARS-CoV-2 yuav ua rau txoj hauv kev los muab kev tiv thaiv tsis yog tsuas yog cov neeg tsis muaj zog nrog lub cev tsis muaj zog thiab cov neeg muaj tus kab mob tab sis tseem yuav tiv thaiv lwm tus neeg noj qab haus huv los ntawm kev cog lus. tus kab mob no thaum siv nrog cov tshuaj tiv thaiv no.
***
***
References:
- UCLH 2020. Xov xwm. UCLH koob tshuaj thawj tus neeg mob hauv ntiaj teb hauv Covid-19 kev sim tshuaj tiv thaiv kab mob. Luam tawm Lub Kaum Ob Hlis 25, 2020. Muaj nyob online ntawm https://www.uclhospitals.brc.nihr.ac.uk/news/uclh-doses-first-patient-world-covid-19-antibody-trial Tau txais los ntawm 26 Lub Kaum Ob Hlis 2020.
- NIH 2020. A Theem III Randomized, Ob-dig muag, Placebo-tswj, Ntau qhov chaw kawm hauv cov neeg laus kom txiav txim siab txog kev nyab xeeb thiab kev ua tau zoo ntawm AZD7442, Cov Khoom Siv Uas Sib xyaw ntawm Ob Monoclonal Antibodies (AZD8895 thiab AZD1061), rau Post-exposure of Prophy COVID 19. Muaj nyob online ntawm https://clinicaltrials.gov/ct2/show/study/NCT04625972 Tau txais los ntawm 26 Lub Kaum Ob Hlis 2020.
- Prasad U., 2020. New Strains of SARS-CoV-2 (tus kab mob lub luag hauj lwm rau COVID-19): Puas yog 'Neutralising Antibodies' Approach yuav teb rau Rapid Mutation?. Kev Tshawb Fawb Tebchaws Europe luam tawm 23 Lub Kaum Ob Hlis 2020. Muaj nyob online ntawm https://www.scientificeuropean.co.uk/covid-19/new-strains-of-sars-cov-2-the-virus-responsible-for-covid-19-could-neutralising-antibodies-approach-be-answer-to-rapid-mutation/ Tau txais los ntawm 26 Lub Kaum Ob Hlis 2020.
- AstraZeneca 2020. Xov xwm tawm. COVID-19 Long-Acting AntiBody (LAAB) ua ke AZD7442 sai sai mus rau theem III kev sim tshuaj. Published 09 October 2020. Muaj nyob online ntawm https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html Tau txais los ntawm 26 Kaum Ob Hlis 2020
***
 has announced neutralising antibody trial against COVID-19 in the UK. The announcement on 25 December 2020 says ‘’UCLH doses first patient in the world in Covid-19 antibody trial’’ and ‘’ Researchers in the STORM CHASER study led by UCLH virologist Dr Catherine Houlihan have recruited the first participant in the world to the study’’){kind=link}